Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 363 clinical trials
featured
A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

temozolomide
glioblastoma
  • 164 views
  • 24 Nov, 2020
  • 1 location
featured
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO-II)

glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.  

cancer
MRI
bevacizumab
  • 40 views
  • 11 Jun, 2020
  • 1 location
featured
CG01-GBM Standard Chemotherapy versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Glioblastoma Multiforme (GBM)

People who were previously diagnosed with glioblastoma (Grade IV) or Grade III glioma, and now have evidence that their tumor has come back or has started to grow again, and who would otherwise be

brain tumor
glioblastoma
  • 117 views
  • 22 Dec, 2020
  • 1 location
featured
GBM AGILE An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM

People with either a new diagnosis of glioblastoma or with evidence that their tumor has returned or started to grow again may be eligible.  This trial is studying multiple treatment

brain tumor
glioblastoma multiforme
  • 0 views
  • 22 Dec, 2020
  • 1 location
featured
Wake Forest WF-1801 A Single Arm, Pilot Study of Ramipril for Preventing Radiation - Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

People who were just diagnosed with glioblastoma and have yet to get treatment may be eligible.  This trial is investigating whether a common blood pressure drug is helpful to prevent

brain tumor
cancer
  • 2 views
  • 22 Dec, 2020
  • 1 location
featured
OT-15-001 (STELLAR) A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After irradiation and Adjuvant Temozolomide Chemotherapy

it has progressed to a glioblastoma (WHO grade IV astrocytoma) may be eligible to participate.  This study is comparing treatment with CCNU, which is a standard of care treatment, to

brain tumors
brain tumor
astrocytoma
  • 10 views
  • 22 Dec, 2020
  • 1 location
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

> Dose escalation will be guided by a Bayesian logistic regression model with overdose control. Once MTD/ RP2D is declared, glioblastoma patients will be enrolled in the phase II part to further assess

  • 0 views
  • 15 Jun, 2021
  • 18 locations
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The treatment comprises maximal safe resection followed by radiotherapy and chemotherapy. Despite appropriate

  • 15 views
  • 23 Jan, 2021
  • 1 location
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels. Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.

temozolomide
karnofsky performance status
  • 305 views
  • 07 Nov, 2020
  • 2 locations
Safety Study of Cetuximab Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

GERT is a one-armed single-center phase I/II trial. In a first step, dose-escalation of TMZ from 50 mg/m2 to 75mg/m2 together with radiotherapy and cetuximab will be performed. Should safety be proven, the phase II trial will be initiated with the standard dose of 75mg/m2 of TMZ. Cetuximab will be …

temozolomide
neutrophil count
  • 60 views
  • 07 Nov, 2020
  • 1 location